Souhaitez-vous accéder aux communiqués récents ?

Australian needle-free vaccine patch company Vaxxas appoints global pharmaceutical executive to Board as it accelerates product to market.

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concernIn...

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders,...

Ottawa, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The global packaged food market size stood at USD 2.58 trillion in 2024 and is predicted to increase from USD 2.69 trillion in 2025 to reach around USD 3.93...

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aeries Technology, Inc. (NASDAQ: AERT) (“Aeries” or the “Company”), a global leader in AI-powered business transformation and Global Capability Center...

CBAK Energy Reports Third Quarter and First Nine Months of 2025 Unaudited Financial Results

Caledonia Delivers Strong Q3 2025 Revenue Amid Growth Plans ST HELIER, Jersey, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc (“Caledonia” or “the Company”, and, together with...

TRIAL TO BE CONDUCTED BY ADVANCE-ID, A NATIONAL UNIVERSITY OF SINGAPORE LED TRIAL NETWORK, IN PARTNERSHIP WITH BIOVERSYS Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 10, 2025...

Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results...